Literature DB >> 26444794

MAPT H1 Haplotype is Associated with Late-Onset Alzheimer's Disease Risk in APOEɛ4 Noncarriers: Results from the Dementia Genetics Spanish Consortium.

Pau Pastor1,2,3, Fermín Moreno2,4, Jordi Clarimón2,5, Agustín Ruiz6, Onofre Combarros2,7, Miguel Calero2,6, Adolfo López de Munain2,4,8, Maria J Bullido2,9,10, Marian M de Pancorbo11, Eva Carro2,12, Anna Antonell13, Eliecer Coto14, Sara Ortega-Cubero1,2, Isabel Hernandez6, Lluís Tárraga6, Mercè Boada6, Alberto Lleó2,5, Oriol Dols-Icardo2,5, Jaime Kulisevsky2,5,15, José Luis Vázquez-Higuera2,7, Jon Infante2,7, Alberto Rábano2,16, Miguel Ángel Fernández-Blázquez17, Meritxell Valentí17, Begoña Indakoetxea2,4, Myriam Barandiarán2,4, Ana Gorostidi2,8, Ana Frank-García2,10,18, Isabel Sastre2,9,10, Elena Lorenzo1,2, María A Pastor2,19,20, Xabier Elcoroaristizabal11, Martina Lennarz21, Wolfang Maier21,22, Alfredo Rámirez21,23, Manuel Serrano-Ríos24, Suzee E Lee25, Pascual Sánchez-Juan2,7.   

Abstract

The MAPT H1 haplotype has been linked to several disorders, but its relationship with Alzheimer's disease (AD) remains controversial. A rare variant in MAPT (p.A152T) has been linked with frontotemporal dementia (FTD) and AD. We genotyped H1/H2 and p.A152T MAPT in 11,572 subjects from Spain (4,327 AD, 563 FTD, 648 Parkinson's disease (PD), 84 progressive supranuclear palsy (PSP), and 5,950 healthy controls). Additionally, we included 101 individuals from 21 families with genetic FTD. MAPT p.A152T was borderline significantly associated with FTD [odds ratio (OR) = 2.03; p = 0.063], but not with AD. MAPT H1 haplotype was associated with AD risk (OR = 1.12; p = 0.0005). Stratification analysis showed that this association was mainly driven by APOE ɛ4 noncarriers (OR = 1.14; p = 0.0025). MAPT H1 was also associated with risk for PD (OR = 1.30; p = 0.0003) and PSP (OR = 3.18; p = 8.59 × 10-8) but not FTD. Our results suggest that the MAPT H1 haplotype increases the risk of PD, PSP, and non-APOE ɛ4 AD.

Entities:  

Keywords:  A152T; Alzheimer’s disease; H1H2; MAPT; frontotemporal dementia; genetic association

Mesh:

Substances:

Year:  2016        PMID: 26444794     DOI: 10.3233/JAD-150555

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  17 in total

Review 1.  Neuropathology of genetic synucleinopathies with parkinsonism: Review of the literature.

Authors:  Susanne A Schneider; Roy N Alcalay
Journal:  Mov Disord       Date:  2017-11       Impact factor: 10.338

Review 2.  Genetics of Frontotemporal Dementia.

Authors:  Diana A Olszewska; Roisin Lonergan; Emer M Fallon; Tim Lynch
Journal:  Curr Neurol Neurosci Rep       Date:  2016-12       Impact factor: 5.081

3.  Genetic Comparison of Symptomatic and Asymptomatic Persons With Alzheimer Disease Neuropathology.

Authors:  Sarah E Monsell; Charles Mock; David W Fardo; Sarah Bertelsen; Nigel J Cairns; Catherine M Roe; Sally R Ellingson; John C Morris; Alison M Goate; Walter A Kukull
Journal:  Alzheimer Dis Assoc Disord       Date:  2017 Jul-Sep       Impact factor: 2.703

4.  Gene expression, methylation and neuropathology correlations at progressive supranuclear palsy risk loci.

Authors:  Mariet Allen; Jeremy D Burgess; Travis Ballard; Daniel Serie; Xue Wang; Curtis S Younkin; Zhifu Sun; Naomi Kouri; Saurabh Baheti; Chen Wang; Minerva M Carrasquillo; Thuy Nguyen; Sarah Lincoln; Kimberly Malphrus; Melissa Murray; Todd E Golde; Nathan D Price; Steven G Younkin; Gerard D Schellenberg; Yan Asmann; Tamas Ordog; Julia Crook; Dennis Dickson; Nilüfer Ertekin-Taner
Journal:  Acta Neuropathol       Date:  2016-04-26       Impact factor: 17.088

Review 5.  Interactions of pathological proteins in neurodegenerative diseases.

Authors:  Tara L Spires-Jones; Johannes Attems; Dietmar Rudolf Thal
Journal:  Acta Neuropathol       Date:  2017-04-11       Impact factor: 17.088

Review 6.  Meta-analysis of the association between variants in MAPT and neurodegenerative diseases.

Authors:  Cheng-Cheng Zhang; Jun-Xia Zhu; Yu Wan; Lin Tan; Hui-Fu Wang; Jin-Tai Yu; Lan Tan
Journal:  Oncotarget       Date:  2017-07-04

7.  The unexpected co-occurrence of GRN and MAPT p.A152T in Basque families: Clinical and pathological characteristics.

Authors:  Fermin Moreno; Begoña Indakoetxea; Myriam Barandiaran; María Cristina Caballero; Ana Gorostidi; Francesc Calafell; Alazne Gabilondo; Mikel Tainta; Miren Zulaica; José F Martí Massó; Adolfo López de Munain; Pascual Sánchez-Juan; Suzee E Lee
Journal:  PLoS One       Date:  2017-06-08       Impact factor: 3.240

8.  A152T tau allele causes neurodegeneration that can be ameliorated in a zebrafish model by autophagy induction.

Authors:  Ana Lopez; Suzee E Lee; Kevin Wojta; Eliana Marisa Ramos; Eric Klein; Jason Chen; Adam L Boxer; Maria Luisa Gorno-Tempini; Daniel H Geschwind; Lars Schlotawa; Nikolay V Ogryzko; Eileen H Bigio; Emily Rogalski; Sandra Weintraub; Marsel M Mesulam; Angeleen Fleming; Giovanni Coppola; Bruce L Miller; David C Rubinsztein
Journal:  Brain       Date:  2017-04-01       Impact factor: 13.501

Review 9.  Tau at the interface between neurodegeneration and neuroinflammation.

Authors:  Alessandro Didonna
Journal:  Genes Immun       Date:  2020-10-03       Impact factor: 2.676

10.  Overlap between Parkinson disease and Alzheimer disease in ABCA7 functional variants.

Authors:  Karen Nuytemans; Lizmarie Maldonado; Aleena Ali; Krista John-Williams; Gary W Beecham; Eden Martin; William K Scott; Jeffery M Vance
Journal:  Neurol Genet       Date:  2016-01-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.